癌症輔助治療 × 癌症輔助治療
結論：證據分歧
PSK 於胃癌、大腸癌術後輔助治療具有罕見的高品質大型 MA 證據鏈（Sakamoto 2007 n=8,009 OS HR 0.
B 🟡 B 初步證據 證據分歧 🚨 high — heavy affiliate marketing in TW community
PSK 於胃癌、大腸癌術後輔助治療具有罕見的高品質大型 MA 證據鏈（Sakamoto 2007 n=8,009 OS HR 0.88；Oba 2006 n=1,094 OS RR 0.71；2017 NMA n=10,684；2019 SR n=4,246），累計樣本 >18,000、方向一致，且日本 PMDA 自 1977 年起核准為處方藥、NCI PDQ 與 NIH-ODS 替代來源亦判 supportive 0.85。
然而由於 ASCO/NCCN/ESMO/SIO 一致不推薦、缺乏現代西方族群 RCT、台灣與美國均未核准、Krestin Rx 與 OTC turkey tail 補充劑無法等同，整體無法達 S tier。
獨立判讀為 A（中度證據），但必須以 dispute_review 處理 JP-vs-Western 法域分裂。
⚖️
評分透明度
所有分數由 7 層證據引擎計算，過程公開可查原始分數 0.63
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
B · 證據分歧
信心度
67%
證據方向大致一致
證據層級
E2
多篇高品質統合分析（≥2 篇一致）
▸查看完整決策路徑（audit trail）
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.625
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (4 篇 > 0 negative)
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 1 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer
結論：PSK + chemo significantly improved OS vs chemo alone; HR 0.88 (95% CI 0.79-0.98; P=0.018), no significant heterogeneity across 8 RCTs.
前往 PubMed
Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials
結論：PSK + chemo improved both OS and DFS: OS RR 0.71 (95% CI 0.55-0.90; P=0.006); DFS RR 0.72 (95% CI 0.58-0.90; P=0.003) across 3 centrally randomized RCTs.
前往 PubMed
Can polysaccharide K improve therapeutic efficacy and safety in gastrointestinal cancer? a systematic review and network meta-analysis
結論：PSK + chemo significantly improved 1-5y OS and 1-7y DFS across 23 RCTs (n=10,684); PSK+IV chemo ranked best for 3y/5y OS. Safety: reduced nausea/vomiting (OR 0.53, 95% CI 0.31-0.91) and leukopenia (OR 0.60, 95% CI 0.43-0.83).
前往 PubMed
Coriolus Versicolor and Ganoderma Lucidum Related Natural Products as an Adjunct Therapy for Cancers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
結論：Adjunct Coriolus/Ganoderma significantly lowered mortality (HR 0.82, 95% CI 0.72-0.94) and improved total efficacy (RR 1.30, 95% CI 1.09-1.55) across 23 RCTs.
前往 PubMed
L4a US FDA
謹慎
Turkey tail are known to have anti-cancer, antiviral, antibacterial and antifungal effects as well as immune modulating effects. ... The claims on your website establish that your products are drugs under section 201(g)(1)(B) of the FD&C Act because they were intended for use in the cure, mitigation, treatment, or prevention of disease. 來源↗
L4b EU EFSA
反對
Commission Implementing Decision of 6 December 2021 (C(2021) 8744 final) terminating the procedure for authorising the placing on the market within the Union of the novel food 'Coriolus versicolor' without updating the Union list of novel foods pursuant to Regulation (EU) 2015/2283. 來源↗
L4c UK NHS
未表態
— 本適應症無對應資料
L4d TW TFDA / 衛福部
中性
— 本適應症無對應資料
L4e WHO
未表態
— 本適應症無對應資料
L5a NIH Office of Dietary Supplements
支持
— 本適應症無對應資料
L5b Mayo Clinic
謹慎
Compounds found in turkey tail mushrooms can change how certain anticancer drugs (e.g., cyclophosphamide, tamoxifen) are processed and removed from the body, which may alter the efficacy of the anti-cancer drug and cause more side effects. 來源↗
L5c Cleveland Clinic
未表態
— 本適應症無對應資料
L5d Harvard Health
未表態
— 本適應症無對應資料
L5e Specialty Society (condition-mapped)
中性
Polysaccharide-K (PSK), a proprietary preparation of Trametes versicolor, has been used in Japan as an adjuvant cancer therapy for over 30 years and is recommended in some Japanese clinical practice guidelines for gastric and colorectal cancer. A 2006 meta-analysis of randomized controlled trials in curatively resected colorectal cancer (Oba et al., n=1,094 patients across 3 trials in original … 來源↗
PTT · Dcard · Mobile01 彙整自公開論壇討論，非統計抽樣，僅反映社群風向。
廣告 / 業配密度 極高
低中高
📍立場總覽
用於『癌症輔助治療』雖是雲芝在中文圈最主要的用途，台灣社群卻幾乎沒有針對雲芝單方的鄉民實測討論。PTT 抗癌板（Anti-Cancer）與 Dcard 癌症版確有大量癌友交流化療期保健品，但壓倒性集中在魚油、褐藻醣膠、左旋麩醯胺酸、白蛋白、益生菌與靈芝/牛樟芝，雲芝極少被單獨提名或分享心得。可見的『雲芝抗癌/化放療輔助』內容幾乎全來自香港商業電商與業配（Vita Green 盈活雲芝『癌症治療專用營養品』、hyy.com.hk、she.com、healthyD、FB medicalinspire），業配密度極高、立場不可信。少數具參考價值的在地/港式衛教訊號是腫瘤科醫師提醒『化放療期間自行併服雲芝/靈芝，約一成病患因肝腎功能受損或白血球/血小板下降而須暫停治療』。整體屬社群聲量薄弱、業配主導的標的，不杜撰鄉民聲量。
💬社群實感
無共識（台灣 PTT 抗癌板/Dcard 癌症版未見以雲芝單方輔助化放療的多人實測心得；癌友輔助保健討論集中於魚油、褐藻醣膠、左旋麩醯胺酸、靈芝/牛樟芝，雲芝鮮少被單獨提名）
破解迷思 社群最常見的 4 個誤解
✕
迷思把雲芝與靈芝混為一談、視為可互相替代的『抗癌真菌』
✓
事實雲芝（Coriolus/Trametes versicolor，火雞尾）主成分為 PSK/PSP 多醣，靈芝為三萜＋多醣，研究與作用面向不同，社群與業配最常見錯誤是兩者效果等同
✕
迷思把日本處方藥 Krestin/PSK（CM-101 菌株標準化製劑、PMDA 1977 核准用於胃癌/大腸癌術後輔助）的臨床數據，直接套用到市售 OTC 雲芝菌絲體/PSP 補充劑
✓
事實兩者菌株、純度、劑量、品質控管不可等同，社群常以此高估療效
✕
迷思認為『雲芝是天然菇類、化療期間吃很安全』
✓
事實實際上腫瘤科醫師提醒療程期間自行併服恐影響肝腎功能、降低白血球/血小板而須暫停治療，並有 CYP 介導之化療藥物交互作用風險（如 cyclophosphamide、tamoxifen、5-FU、doxorubicin）
✕
迷思把『增強免疫即等於抗癌、可縮小腫瘤/延長存活』當成既定事實
✓
事實多為香港保健品電商業配話術，且在台灣此類抗癌/化放療輔助宣稱違反食安法第28條
🩹 社群通報的副作用
- 化放療療程期間併服恐致肝腎功能異常、白血球/血小板下降而須暫停治療（腫瘤科醫師衛教轉述，約一成病患）
- 少數人反映腹瀉、噁心等輕微腸胃不適
🏷️ 社群熱議品牌
依論壇被提及頻率，非銷售或品質排序。
- Vita Green 維特健靈 盈活雲芝（香港品牌，『癌症治療專用營養品』，中文圈雲芝抗癌討論最常見曝光，業配性質）
- 葡萄王 雲芝王（台灣端偶被帶到的商品名，鄉民實測討論極少）
⚠️ 列出僅代表「TW 社群討論度高」，不代表本站推薦或背書。本站不販售任何產品、無導購連結。
- 標準腫瘤治療（手術、化療、放療、免疫治療）
- 標靶治療
- 緩和照護（與抗癌治療併行）
查看 ClaimReview 結構化資料 (JSON-LD)
{
"@context": "https://schema.org",
"@type": "ClaimReview",
"url": "https://gpt-dict.com/claim/CLM-COND-cancer-adjunct-INT-coriolus-versicolor-001/",
"datePublished": "2026-06-01",
"author": {
"@type": "Organization",
"name": "gpt-dict.com",
"url": "https://gpt-dict.com"
},
"claimReviewed": "癌症輔助治療能改善癌症輔助治療",
"inLanguage": "zh-TW",
"itemReviewed": {
"@type": "Claim",
"appearance": []
},
"reviewRating": {
"@type": "Rating",
"ratingValue": 3,
"bestRating": 5,
"worstRating": 1,
"alternateName": "🟡 B 初步證據"
}
}